Focus: Chia Tai TianQing is a China-based pharmaceutical company focused on small molecules and generics across oncology, respiratory, infectious diseases, immunology, and hematology. The company operates from Lianyungang and maintains a substantial clinical trial portfolio.
Profile data last refreshed 2d ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Chia Tai TianQing Pharmaceutical Group to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
ANDA-approved generic with established clinical utility but declining exclusivity; tubulin-targeting mechanism used as cash generator.
Help build intelligence for Chia Tai TianQing Pharmaceutical Group
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Chia Tai TianQing Pharmaceutical Group's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
NK1 receptor antagonist in post-LOE phase; supported by robust data on acute and delayed emesis prevention.
Pre-launch ANDA filing targeting large HR+ breast cancer market; entry into high-value oncology segment.
Estrogen receptor antagonist; post-LOE generic with sustained demand in endocrine therapy.
Pre-launch ANDA; differentiated mechanism vs. GnRH agonists with castration benefit.
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo